Established in April 1993 by Dr. Alex Kozak, D-Pharm is a specialty pharmaceutical company that designs and develops innovative drugs for the treatment of the most devastating brain disorders. The Company has developed two
unique platform technologies that generate lipid–like medicines which utilise lipid specific mechanisms and lipid-related pathways in living cells. The Company’s drug candidates are New Chemical Entities protected by patents and patent applications in a wide range of countries.
The Company has two products in advanced clinical development (Phase II):
# DP-b99 for Stroke; and
# DP-VPA for Epilepsy.
Additional therapeutic applications for DP-b99 include: Traumatic Brain Injury (TBI) and diminishing the risk of brain damage associated with Coronary Artery Bypass Graft surgery (CABG); and for DP-VPA include Bipolar disorder and prophylaxis of Migraine.
In addition, the Company possesses a substantial pipeline of pre-clinical candidates for treatment of neuro-degenerative diseases, other CNS disorders and cancer. The most advanced of these candidates is DP-460 for the treatment of Alzheimer’s disease.
The Company’s offices, research and development laboratories and pilot manufacturing plant are located in the Kiryat Weizmann Science Park in Nes Ziona, Israel.